Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200207103> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W4200207103 endingPage "S735" @default.
- W4200207103 startingPage "S734" @default.
- W4200207103 abstract "Abstract Background Gram-negative bacterial resistance is a global health problem. Limited treatment options exist, especially for carbapenem resistant (CR) pathogens containing metallo-β-lactamases (MBLs) and multidrug resistant non-lactose fermenting bacteria. Cefiderocol (CFDC) retains activity against resistant strains. We describe the objectives, design, and early results of PROVE, a real world retrospective study of CFDC use. Methods PROVE is a multi-center, chart review study of CFDC use for resistant Gram-negative infections (GNI). Cases were eligible if they received ≥ 72 hrs of CFDC. Demographics, comorbidity, pathogen, infection site, and treatment course were assessed. Outcomes included all-cause 14-day and inpatient mortality and length of stay (LOS). Clinical resolution was defined by documentation that clinical signs and/or symptoms had resolved or improved without relapse. Results 24 patients who were treated with CFDC at 2 sites were included to date. Median age was 48 years (Range: 19 - 69 years); 33% were female. The most common comorbidity was diabetes (n=7, 29%). Median total ICU LOS was 36 days. Targeted treatment of documented GNI without preceding failure of prior therapy accounted for 71% of CFDC use. Empirical and salvage treatments accounted for 4% and 25% respectively (Table 1). Median time from admission to 1st CFDC dose was 21 days. Acinetobacter baumannii and Pseudomonas aeruginosa accounted for > 75% of isolates (Fig.1). 92% of patients had CR isolates; > 50% were respiratory. Sensitivity to CFDC was tested in 58% of which 71% were sensitive. All-cause 14-day post-CFDC mortality was 13% (95% CI: 2, 27) and overall hospital mortality 25% (95% CI: 6, 44). Clinical resolution was reached in 54% (95% CI: 33, 76). Median post-CFDC LOS was 40 days. Outcomes were stratified by key covariates (Table 2). Conclusion We present initial data for real world use of CFDC for resistant GNI. Patients were complex with multiple comorbidities, some hospitalized for long periods before their index GNI. Outcomes largely reflect this patient population. Additional data are needed to determine the optimal role of CFDC. PROVE offers an opportunity to see how CFDC is being utilized in various settings as well as a first look at key, real world outcomes. Disclosures Stephen Marcella, MD, MPH, Shionogi, Inc (Employee) Steven Smoke, PharmD, Karius (Advisor or Review Panel member)Shionogi (Scientific Research Study Investigator, Advisor or Review Panel member) Ryan K. Shields, PharmD, MS, Shionogi (Consultant, Research Grant or Support) David van Duin, MD, PhD, Entasis (Advisor or Review Panel member)genentech (Advisor or Review Panel member)Karius (Advisor or Review Panel member)Merck (Grant/Research Support, Advisor or Review Panel member)Pfizer (Consultant, Advisor or Review Panel member)Qpex (Advisor or Review Panel member)Shionogi (Grant/Research Support, Scientific Research Study Investigator, Advisor or Review Panel member)Utility (Advisor or Review Panel member)" @default.
- W4200207103 created "2021-12-31" @default.
- W4200207103 creator A5019596297 @default.
- W4200207103 creator A5044685243 @default.
- W4200207103 creator A5060214913 @default.
- W4200207103 creator A5068286313 @default.
- W4200207103 creator A5077066823 @default.
- W4200207103 creator A5090336151 @default.
- W4200207103 date "2021-11-01" @default.
- W4200207103 modified "2023-09-27" @default.
- W4200207103 title "1291. PROVE (Retrospective Cefiderocol Chart Review) Study of Real-World Outcomes and Safety in the Treatment of Patients with Gram-negative Bacterial Infections in the US and Europe" @default.
- W4200207103 doi "https://doi.org/10.1093/ofid/ofab466.1483" @default.
- W4200207103 hasPublicationYear "2021" @default.
- W4200207103 type Work @default.
- W4200207103 citedByCount "0" @default.
- W4200207103 crossrefType "journal-article" @default.
- W4200207103 hasAuthorship W4200207103A5019596297 @default.
- W4200207103 hasAuthorship W4200207103A5044685243 @default.
- W4200207103 hasAuthorship W4200207103A5060214913 @default.
- W4200207103 hasAuthorship W4200207103A5068286313 @default.
- W4200207103 hasAuthorship W4200207103A5077066823 @default.
- W4200207103 hasAuthorship W4200207103A5090336151 @default.
- W4200207103 hasBestOaLocation W42002071031 @default.
- W4200207103 hasConcept C126322002 @default.
- W4200207103 hasConcept C167135981 @default.
- W4200207103 hasConcept C177713679 @default.
- W4200207103 hasConcept C187212893 @default.
- W4200207103 hasConcept C197934379 @default.
- W4200207103 hasConcept C2776315533 @default.
- W4200207103 hasConcept C2777637488 @default.
- W4200207103 hasConcept C2779159551 @default.
- W4200207103 hasConcept C523546767 @default.
- W4200207103 hasConcept C54355233 @default.
- W4200207103 hasConcept C71924100 @default.
- W4200207103 hasConcept C86803240 @default.
- W4200207103 hasConceptScore W4200207103C126322002 @default.
- W4200207103 hasConceptScore W4200207103C167135981 @default.
- W4200207103 hasConceptScore W4200207103C177713679 @default.
- W4200207103 hasConceptScore W4200207103C187212893 @default.
- W4200207103 hasConceptScore W4200207103C197934379 @default.
- W4200207103 hasConceptScore W4200207103C2776315533 @default.
- W4200207103 hasConceptScore W4200207103C2777637488 @default.
- W4200207103 hasConceptScore W4200207103C2779159551 @default.
- W4200207103 hasConceptScore W4200207103C523546767 @default.
- W4200207103 hasConceptScore W4200207103C54355233 @default.
- W4200207103 hasConceptScore W4200207103C71924100 @default.
- W4200207103 hasConceptScore W4200207103C86803240 @default.
- W4200207103 hasIssue "Supplement_1" @default.
- W4200207103 hasLocation W42002071031 @default.
- W4200207103 hasLocation W42002071032 @default.
- W4200207103 hasOpenAccess W4200207103 @default.
- W4200207103 hasPrimaryLocation W42002071031 @default.
- W4200207103 hasRelatedWork W1481826480 @default.
- W4200207103 hasRelatedWork W2060488837 @default.
- W4200207103 hasRelatedWork W2123498714 @default.
- W4200207103 hasRelatedWork W2143939248 @default.
- W4200207103 hasRelatedWork W2361808727 @default.
- W4200207103 hasRelatedWork W2613293866 @default.
- W4200207103 hasRelatedWork W3004727499 @default.
- W4200207103 hasRelatedWork W3048013375 @default.
- W4200207103 hasRelatedWork W3108408720 @default.
- W4200207103 hasRelatedWork W3201577336 @default.
- W4200207103 hasVolume "8" @default.
- W4200207103 isParatext "false" @default.
- W4200207103 isRetracted "false" @default.
- W4200207103 workType "article" @default.